About the project
Join an interdisciplinary PhD exploring how psychiatric drugs interact with the gut microbiome and how these interactions may influence mental health and treatment response. Combining microbiology, chemical biology and cutting-edge sequencing approaches, you will uncover drug-microbiome mechanisms and investigate new opportunities to improve mental health resilience and therapeutic outcomes.
Mental health disorders affect millions of people worldwide, yet therapeutic responses to psychiatric medications vary considerably between individuals. Understanding the biological factors that contribute to this variability could support the development of more personalised and effective mental health treatments.
The gut microbiome is increasingly recognised as an important component of the gut-brain axis and may influence both mental health and responses to therapeutic interventions. Our preliminary research shows that psychiatric drugs can alter gut microbial communities and their production of neuroprotective metabolites, with effects differing between individual microbiomes. However, we still do not know much about which gut microorganisms directly interact with these drugs, their molecular targets, or the pathways through which these interactions alter microbial function. This project will address this gap by moving beyond observations to define drug-microbe interactions at the cellular and molecular level.
The project will combine chemical synthesis to generate labelled psychiatric drugs, which will be applied to microbiome models, alongside flow cytometry and metagenomic sequencing to identify microorganisms that interact directly with these compounds. Proteomics and transcriptomics will uncover the molecular mechanisms involved. Clinical psychiatry expertise will be integrated throughout the project, providing access to patient samples, interpretation of findings and their clinical relevance. Together, these approaches will bridge chemistry, microbiology and psychiatry to provide a mechanistic understanding of drug-microbiome interactions and their potential implications for treatment response.
You will receive interdisciplinary training spanning microbiology, microbiome science, chemical biology, molecular biology and multi-omics, working across Biological Sciences and Chemistry, with support from Clinical Sciences.